Does the media favor ARWR or GPCR?

In the previous week, Structure Therapeutics had 2 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 7 mentions for Structure Therapeutics and 5 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.46 beat Structure Therapeutics' score of 0.50 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ABVX or GPCR?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A

Is ABVX or GPCR more profitable?

Structure Therapeutics' return on equity of -24.91% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Structure Therapeutics N/A -24.91% -23.67%

Does the media refer more to ABVX or GPCR?

In the previous week, Abivax had 3 more articles in the media than Structure Therapeutics. MarketBeat recorded 10 mentions for Abivax and 7 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.50 beat Abivax's score of 0.34 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Structure Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PRAX or GPCR more profitable?

Structure Therapeutics' return on equity of -24.91% beat Praxis Precision Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines N/A -43.02% -40.22% Structure Therapeutics N/A -24.91% -23.67%

Does the media refer more to PRAX or GPCR?

In the previous week, Praxis Precision Medicines had 3 more articles in the media than Structure Therapeutics. MarketBeat recorded 10 mentions for Praxis Precision Medicines and 7 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.50 beat Praxis Precision Medicines' score of 0.25 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Structure Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GPCR or CYTK?

In the previous week, Cytokinetics had 3 more articles in the media than Structure Therapeutics. MarketBeat recorded 10 mentions for Cytokinetics and 7 mentions for Structure Therapeutics. Cytokinetics' average media sentiment score of 0.60 beat Structure Therapeutics' score of 0.50 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GPCR or KRYS?

In the previous week, Krystal Biotech had 3 more articles in the media than Structure Therapeutics. MarketBeat recorded 10 mentions for Krystal Biotech and 7 mentions for Structure Therapeutics. Krystal Biotech's average media sentiment score of 1.13 beat Structure Therapeutics' score of 0.50 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Structure Therapeutics (GPCR) Competitors

$41.53 +0.28 (+0.68%)

Closing price 04:00 PM Eastern

Extended Trading

$42.20 +0.67 (+1.61%)

As of 07:58 PM Eastern

Compare

GPCR vs. ARWR, ABVX, PRAX, CYTK, and KRYS

Should you buy Structure Therapeutics stock or one of its competitors? MarketBeat compares Structure Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Structure Therapeutics include Arrowhead Pharmaceuticals (ARWR), Abivax (ABVX), Praxis Precision Medicines (PRAX), Cytokinetics (CYTK), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.

How does Structure Therapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Structure Therapeutics had 2 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 7 mentions for Structure Therapeutics and 5 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.46 beat Structure Therapeutics' score of 0.50 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.35, meaning that its stock price is 235% less volatile than the broader market.

Arrowhead Pharmaceuticals currently has a consensus target price of $87.80, suggesting a potential upside of 24.13%. Structure Therapeutics has a consensus target price of $109.25, suggesting a potential upside of 163.06%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89

Structure Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Structure Therapeutics' return on equity of -24.91% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Structure Therapeutics	N/A	-24.91%	-23.67%

Arrowhead Pharmaceuticals has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	12.01	-$1.63M	-$2.15	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Summary

Structure Therapeutics beats Arrowhead Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Structure Therapeutics (NASDAQ:GPCR) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

Structure Therapeutics' return on equity of -24.91% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Structure Therapeutics	N/A	-24.91%	-23.67%

Structure Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Abivax has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.35, suggesting that its stock price is 235% less volatile than the broader market.

47.9% of Abivax shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Abivax had 3 more articles in the media than Structure Therapeutics. MarketBeat recorded 10 mentions for Abivax and 7 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.50 beat Abivax's score of 0.34 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Structure Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax currently has a consensus price target of $130.08, suggesting a potential upside of 32.69%. Structure Therapeutics has a consensus price target of $109.25, suggesting a potential upside of 163.06%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89

Summary

Structure Therapeutics beats Abivax on 11 of the 14 factors compared between the two stocks.

How does Structure Therapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Structure Therapeutics (NASDAQ:GPCR) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

In the previous week, Praxis Precision Medicines had 3 more articles in the media than Structure Therapeutics. MarketBeat recorded 10 mentions for Praxis Precision Medicines and 7 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.50 beat Praxis Precision Medicines' score of 0.25 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Structure Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Praxis Precision Medicines has a beta of 2.71, meaning that its stock price is 171% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.35, meaning that its stock price is 235% less volatile than the broader market.

Structure Therapeutics' return on equity of -24.91% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Structure Therapeutics	N/A	-24.91%	-23.67%

Structure Therapeutics has lower revenue, but higher earnings than Praxis Precision Medicines. Structure Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	784.75	-$303.27M	-$13.37	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Praxis Precision Medicines presently has a consensus target price of $572.72, suggesting a potential upside of 137.98%. Structure Therapeutics has a consensus target price of $109.25, suggesting a potential upside of 163.06%. Given Structure Therapeutics' higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89

Summary

Structure Therapeutics beats Praxis Precision Medicines on 8 of the 14 factors compared between the two stocks.

How does Structure Therapeutics compare to Cytokinetics?

Structure Therapeutics (NASDAQ:GPCR) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Structure Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Cytokinetics	-784.02%	N/A	-52.86%

In the previous week, Cytokinetics had 3 more articles in the media than Structure Therapeutics. MarketBeat recorded 10 mentions for Cytokinetics and 7 mentions for Structure Therapeutics. Cytokinetics' average media sentiment score of 0.60 beat Structure Therapeutics' score of 0.50 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Structure Therapeutics presently has a consensus price target of $109.25, indicating a potential upside of 163.06%. Cytokinetics has a consensus price target of $99.30, indicating a potential upside of 48.05%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Structure Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

Structure Therapeutics has a beta of -1.35, suggesting that its stock price is 235% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

Structure Therapeutics has higher earnings, but lower revenue than Cytokinetics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Cytokinetics	$88.04M	94.79	-$784.96M	-$6.84	N/A

91.8% of Structure Therapeutics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by insiders. Comparatively, 2.6% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Structure Therapeutics beats Cytokinetics on 9 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Krystal Biotech?

Structure Therapeutics (NASDAQ:GPCR) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

Krystal Biotech has a net margin of 53.92% compared to Structure Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Krystal Biotech	53.92%	19.25%	17.62%

Structure Therapeutics presently has a consensus target price of $109.25, suggesting a potential upside of 163.06%. Krystal Biotech has a consensus target price of $324.11, suggesting a potential upside of 3.75%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Structure Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by company insiders. Comparatively, 13.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Krystal Biotech had 3 more articles in the media than Structure Therapeutics. MarketBeat recorded 10 mentions for Krystal Biotech and 7 mentions for Structure Therapeutics. Krystal Biotech's average media sentiment score of 1.13 beat Structure Therapeutics' score of 0.50 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Krystal Biotech	$389.13M	23.67	$204.83M	$7.48	41.77

Structure Therapeutics has a beta of -1.35, meaning that its share price is 235% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

Summary

Krystal Biotech beats Structure Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Structure Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GPCR vs. The Competition

Export

Metric	Structure Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.93B	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.61%
P/E Ratio	-47.74	18.83	24.65	23.63
Price / Sales	N/A	290.84	500.87	105.21
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	1.66	8.00	10.43	6.70
Net Income	-$141.20M	$23.89M	$3.56B	$337.26M
7 Day Performance	10.60%	-3.49%	-1.39%	-1.41%
1 Month Performance	6.21%	1.03%	0.86%	1.15%
1 Year Performance	90.24%	34.39%	19.42%	22.61%

Structure Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GPCR Structure Therapeutics	2.9569 of 5 stars	$41.53 +0.7%	$109.25 +163.1%	+101.1%	$2.93B	N/A	N/A	136	News Coverage Gap Down
ARWR Arrowhead Pharmaceuticals	3.0152 of 5 stars	$75.20 -3.5%	$87.80 +16.8%	+342.5%	$10.97B	$829.45M	N/A	400	Positive News
ABVX Abivax	3.2742 of 5 stars	$129.69 -2.2%	$131.77 +1.6%	+1,216.9%	$10.34B	N/A	N/A	61	High Trading Volume
PRAX Praxis Precision Medicines	2.7733 of 5 stars	$335.16 -4.2%	$584.00 +74.2%	+462.4%	$9.34B	N/A	N/A	110	Gap Up
CYTK Cytokinetics	3.2532 of 5 stars	$73.68 -4.0%	$99.30 +34.8%	+106.6%	$9.17B	$105.82M	N/A	250	Insider Trade Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GPCR) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Structure Therapeutics (GPCR) Competitors

GPCR vs. ARWR, ABVX, PRAX, CYTK, and KRYS

How does Structure Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Structure Therapeutics compare to Abivax?

Summary

How does Structure Therapeutics compare to Praxis Precision Medicines?

Summary

How does Structure Therapeutics compare to Cytokinetics?

Summary

How does Structure Therapeutics compare to Krystal Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR vs. The Competition

Structure Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Structure Therapeutics (GPCR) Competitors

GPCR vs. ARWR, ABVX, PRAX, CYTK, and KRYS

How does Structure Therapeutics compare to Arrowhead Pharmaceuticals?

Do institutionals & insiders hold more shares of ARWR or GPCR?

Does the media favor ARWR or GPCR?

Which has more risk & volatility, ARWR or GPCR?

Do analysts recommend ARWR or GPCR?

Is ARWR or GPCR more profitable?

Which has higher valuation and earnings, ARWR or GPCR?

Summary

How does Structure Therapeutics compare to Abivax?

Is ABVX or GPCR more profitable?

Which has stronger earnings and valuation, ABVX or GPCR?

Which has more volatility and risk, ABVX or GPCR?

Do insiders & institutionals believe in ABVX or GPCR?

Does the media refer more to ABVX or GPCR?

Do analysts rate ABVX or GPCR?

Summary

How does Structure Therapeutics compare to Praxis Precision Medicines?

Does the media refer more to PRAX or GPCR?

Do insiders and institutionals believe in PRAX or GPCR?

Which has more volatility & risk, PRAX or GPCR?

Is PRAX or GPCR more profitable?

Which has better valuation and earnings, PRAX or GPCR?

Do analysts rate PRAX or GPCR?

Summary

How does Structure Therapeutics compare to Cytokinetics?

Is GPCR or CYTK more profitable?

Does the media prefer GPCR or CYTK?

Do analysts prefer GPCR or CYTK?

Which has more risk & volatility, GPCR or CYTK?

Which has preferable valuation and earnings, GPCR or CYTK?

Do institutionals & insiders believe in GPCR or CYTK?

Summary

How does Structure Therapeutics compare to Krystal Biotech?

Is GPCR or KRYS more profitable?

Do analysts rate GPCR or KRYS?

Do institutionals and insiders believe in GPCR or KRYS?

Does the media refer more to GPCR or KRYS?

Which has preferable earnings and valuation, GPCR or KRYS?

Which has more volatility and risk, GPCR or KRYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR vs. The Competition

Structure Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools